RxDoctor Payments Data

Nisha Gupta

Family · Lebanon, PANPI 1417305335

Payments from drug & device makers

$805in general payments, 2019–2025

Across 39 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$139
  • Novartis$99
  • Amgen$96
  • Pfizer$87
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$77
  • AstraZeneca$69
  • plus $237 from 6 others

What the payments were for

  • Food & beverage$805100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$805 in reported general payments places this provider in the 65th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$23,223
Medicare patients
189
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban409$415,385
XareltoRivaroxaban134$150,179
EntrestoSacubitril/Valsartan37$40,428
JardianceEmpagliflozin26$33,040
BrilintaTicagrelor37$32,512
Repatha SureclickEvolocumab20$9,851
Metoprolol Succinate449$6,657
Atorvastatin Calcium437$5,213
Flecainide Acetate56$5,107
Dofetilide12$3,925
Potassium Chloride119$2,931
Ranolazine ErRanolazine24$2,741
ClopidogrelClopidogrel Bisulfate273$2,625
Rosuvastatin Calcium132$2,516
Bumetanide69$2,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$87$415,385409 claims
Johnson & JohnsonXarelto$139$150,179134 claims
NovartisEntresto$99$40,42837 claims
Boehringer IngelheimJardiance$40$33,04026 claims
AstraZenecaBrilinta$69$32,51237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,717 family providers in Pennsylvania.

Other family in Lebanon

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →